

QPS STUDY EXPERIENCE ANTIBODY DRUG CONJUGATES

QPS is a leading full-service global CRO with extensive experience conducting antibody drug conjugate (ADC) research offering comprehensive services to ensure successful drug development. Our experienced and dedicated global team provides unmatched support, from preclinical studies to bioanalysis and all phases of clinical trials.

WHY CHOOSE QPS FOR ONCOLOGY STUDIES WITH ADCS?

1. Expert Global Team

- Specialized Expertise: Our team includes a dedicated framework of board-certified oncologists, experienced clinical research coordinators, project managers, and skilled data analysts.
- Patient-Centric Approach: Powerful associations with efficient study sites across Europe, USA and Asia, innovative patient recruitment strategies, and close links with academia, Site Management Organizations (SMOs), and specialist networks.

2. State-of-the-Art Facilities

- Advanced Bioanalysis Laboratories: Equipped with cutting-edge technology for precise method development and assay execution.
- Extensive ADC experience: Conducting Pharmacokinetic, and Immunogenicity ADC/PDC projects using ELISA, ECL, and (Hybrid) LC-MS/MS.

3. Comprehensive Services

- End-to-End Support: From preclinical studies to bioanalysis, and protocol development to regulatory submissions, QPS handles every aspect of your oncology study.
- Customized Solutions: Tailored study designs to meet the specific needs of oncology research, including biomarker analysis and imaging services.

4. Proven Track Record

- Successful Trials: QPS has conducted Phase I IV oncology studies across Asia, Europe and the United States.
- Broad Range of Cancers: Including, but not limited to breast, head & neck, lung, and prostate cancer.
- Global Reach: A large worldwide database of investigators ensures high enrollment rates of patients selected according to strict eligibility criteria. In addition, we have the capability to recruit patients in countries with a high prevalence of cancers.

CLINICAL RESEARCH OPERATIONS

- Project Management
- Clinical Program Management
- Clinical & Medical Monitoring
- Data Management & Biostatistics
- Medical Writing
- Quality Assurance

- Regulatory & Medical Affairs
- Safety & Pharmacovigilance
- Site Selection & Monitoring

Since 1995, QPS has provided discovery, preclinical, and clinical drug development services. An award winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. For more information on QPS, visit www.qps.com, or email infobd@qps.com.





ONCOLOGY KEY OPINION LEADER (KOL) NETWORK

Europe

- Dr. Mindaugas Jievaltas, Urologist | University Hospital Kaunas/Clinic of Modern Oncology | Lithuania
- Dr. Vincas Urbonas, Medical Oncologist | Early Phase Clinical Trials Lead | National Cancer Institute | Lithuania
- Christina Junvik, Masters Biopharmaceutical Sciences | Early Drug Development in Oncology | Sweden


USA

- Dr. Bruno Fang, Oncologist | Director of Clinical Research at Astera Cancer Care | New Jersey
- Dr. Gordon Brown, Uro-Oncologist | Summit Health/New Jersey Urology | New Jersey
- Dr. Raoul Concepcion, Uro-Oncologist | US Urology Chief Medical Officer | Tennessee
- Dr. Gordon Brown, Uro-Oncologist | Summit Health/New Jersey Urology | New Jersey

Taiwan

- Dr. Yen-Hwa Chang, Uro-Oncologist | Taipei Veterans General Hospital | Taiwan
- Dr. Peng-Hui Wang Director, Obstetrics and Gynecology | Taipei Veterans General Hospital | Taiwan
- Dr. See-Tong Pang, Uro-Oncologist | Chang Gung Memorial Hospital (CGMH) | Taiwan

ONCOLOGY CLINICAL TRIALS SITE NETWORK LOCATIONS



Discover how QPS can accelerate your clinical research.

Email: infobd@qps.com | Phone: 512-350-2827 | Website: www.qps.com

